Mereo BipPharma (MREO) Reiterated at Overweight by Cantor Fitzgerald: High-Risk Jan 13, 2026 07:06AM
Cantor Fitzgerald Reiterates Overweight Rating on Mereo BipPharma Group (MREO) Mar 27, 2025 07:38AM
Mereo and Ultragenyx remain top picks at Cantor Fitzgerald Mar 19, 2025 06:43AM
Cantor Fitzgerald Reiterates Overweight Rating on Mereo BipPharma Group (MREO) Mar 17, 2025 06:43AM
Mereo BioPharma (MREO) Prices 12.53M Share Offering at $3.99/sh Jun 14, 2024 07:51AM


Jun 14, 2024 07:50AM Mereo BioPharma Announces Pricing of $50 Million Underwritten Registered Direct Offering of American Depository Shares, Priced At-the-Market
Sep 9, 2021 08:00AM Mereo BioPharma to Participate in Three Upcoming Investor Conferences
Sep 9, 2021 08:00AM Mereo BioPharma to Participate in Three Upcoming Investor Conferences
Jun 30, 2020 07:00AM Mereo BioPharma Strengthens Management Team; Appoints John Lewicki, PhD, as Chief Scientific Officer and Ann Kapoun, PhD, as SVP of Translational Research and Development
Jun 16, 2020 07:00AM Mereo BioPharma Announces Financial Results for the Year Ended December 31, 2019
Jun 4, 2020 07:00AM Mereo BioPharma Announces Completion of $70 Million Private Placement
Mar 27, 2020 08:00AM Business Update and Directorate Change
Feb 28, 2020 07:08AM Mereo BioPharma (MREO) Reports Positive Feedback from Type B End-of-Ph. 2 Meeting with FDA & Outlines Pivotal Ph. 3 Pediatric Study Design for Setrusumab in Osteogenesis Imperfecta
Feb 28, 2020 07:00AM Mereo BioPharma Announces Positive Feedback from Type B End-of-Phase 2 Meeting with the FDA and Outlines Pivotal Phase 3 Pediatric Study Design for Setrusumab in Osteogenesis Imperfecta
Feb 19, 2020 03:00AM Mereo BioPharma Announces Equity Investment of $3 Million from New U.S. Institutional Investor
Feb 12, 2020 08:00AM Mereo BioPharma Announces Update on Distribution Related to Contingent Value Rights Following Recent Oncologie Licensing Agreement for Navicixizumab
Feb 10, 2020 07:00AM Mereo BioPharma Enters into a $5 Million Convertible Equity Financing with Novartis and Announces a Securities Purchase Agreement with Aspire Capital Fund, LLC for up to $28 Million
Jan 14, 2020 07:03AM Mereo BioPharma Group (MERO) Reports Additional Positive Data from Phase 2b ASTEROID Study of Setrusumab in Adults with Osteogenesis Imperfecta; Provides Update on Regulatory Progress
Jan 14, 2020 07:00AM Mereo BioPharma Announces Additional Positive Data from Phase 2b ASTEROID Study of Setrusumab in Adults with Osteogenesis Imperfecta and Provides Update on Regulatory Progress
Jan 13, 2020 07:00AM Mereo BioPharma and Oncologie Enter into Global Licensing Agreement for Navicixizumab
Jan 13, 2020 07:00AM Mereo BioPharma and Oncologie Enter into Global Licensing Agreement for Navicixizumab
Nov 11, 2019 06:30AM Mereo BioPharma’s Setrusumab Demonstrates Dose-Dependent Bone Building and Trend in Fracture Reduction in Phase 2b ASTEROID Study in Adults with Osteogenesis Imperfecta
Oct 7, 2019 08:02AM UPDATE: Mereo BioPharma (MREO) Receives FDA Fast Track Designation for Navicixizumab for Treatment of Heavily Pretreated Ovarian Cancer
Oct 7, 2019 08:00AM Mereo BioPharma Receives FDA Fast Track Designation for Navicixizumab for the Treatment of Heavily Pretreated Ovarian Cancer
Sep 17, 2019 07:00AM Mereo BioPharma Announces Interim Financial Results for the Six Months Ended June 30, 2019 and Provides Corporate Update
Sep 10, 2019 08:00AM Mereo BioPharma to Announce Interim Financial Results for the Six Months Ended June 30, 2019 and Provide Corporate Update on September 17, 2019
Sep 4, 2019 08:00AM Mereo BioPharma Announces Setrusumab 6-Month Phase 2b Data in Osteogenesis Imperfecta Selected for Late-Breaking Oral Presentation at the American Society for Bone and Mineral Research (ASBMR) 2019 An
Jul 16, 2019 08:00AM Mereo BioPharma Appoints Richard Francis as Head of Pharmaceutical Development
Jul 15, 2019 08:06AM Mereo BioPharma (MREO) Announces Successful Type B Meeting with FDA, Outlines Accelerated Approval Pathway for Navicixizumab
Jul 15, 2019 08:00AM Mereo BioPharma Announces Successful Type B Meeting with U.S. FDA and Outlines Accelerated Approval Pathway for Navicixizumab in Advanced Ovarian Cancer
Jun 13, 2019 08:00AM Mereo BioPharma Group plc (“Mereo” or the “Company” or the “Group”) Update on Etigilimab (TIGIT) Partnership
May 30, 2019 05:47AM UPDATE: Mereo BioPharma (MREO) Reports Positive Early 6 Month Data from Open Label Arm of Phase 2b Clinical Study of BPS-804 (setrusumab)
May 30, 2019 02:00AM Mereo BioPharma Group plc Announces Positive Early 6 Month Data from the Open Label Arm of the Phase 2b Clinical Study in Adult Patients with Type I, III or IV Osteogenesis Imperfecta Treated with the
May 3, 2019 12:09PM Mereo BioPharma Group plc (“Mereo” or the “Company” or the “Group”) Intention to Purchase Shares by Trustee of Employee Benefit Trust
Apr 26, 2019 08:00AM Mereo Biopharma to Announce Preliminary Results for the Full Year 2018 and Host Conference Call on April 29, 2019
Apr 26, 2019 08:00AM Mereo Biopharma to Announce Preliminary Results for the Full Year 2018 and Host Conference Call on April 29, 2019
Apr 24, 2019 09:30AM Mereo BioPharma Group plc ("Mereo" or the "Company" or the "Group") Admission to trading on AIM of New Shares and initiation of trading on Nasdaq of American Depositary Shares
Apr 24, 2019 09:30AM Mereo BioPharma Group plc ("Mereo" or the "Company" or the "Group") Admission to trading on AIM of New Shares and initiation of trading on Nasdaq of American Depositary S
Jan 25, 2019 06:13AM Mereo Publicly Files Registration Statement on Form F-4 with U.S. Securities and Exchange Commission
Dec 10, 2018 02:00AM Mereo BioPharma to Present at The BMO Prescriptions for Success Healthcare Conference on 12 December 2018
Dec 5, 2018 08:10AM Proposed Combination of Mereo BioPharma and OncoMed Pharmaceuticals